COLL Stock Recent News

STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report second quarter 2025 financial results before the market opens on Thursday, August 7, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.

Stock buybacks remain one of the most effective tools for boosting share prices, especially when backed by solid fundamentals. When a company is healthy, repurchasing shares reduces the float, enhances earnings per share, and signals confidence to the market.

STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced its Board of Directors has authorized a new share repurchase program to repurchase up to $150 million in common stock through December 31, 2026.

Collegium is shifting focus from opioids to ADHD with Jornay PM, which is showing strong prescription growth and could become a blockbuster product. The company is undervalued relative to peers, with potential for significant upside if Jornay PM delivers on revenue expectations and offsets future patent expirations. Management is strategically reducing debt and maintaining profitability, positioning Collegium for growth and potential shareholder returns through buybacks.

STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:

STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $65 million remaining under the program.

Call Start: 16:30 January 1, 0000 5:05 PM ET Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2025 Earnings Call May 8, 2025 16:30 ET Company Participants Ian Karp - Head, Investor Relations Vikram Karnani - President and Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants Les Sulewski - Truist Securities Serge Belanger - Needham & Co David Amsellem - Piper Sandler Operator Greetings and welcome to the Collegium Pharmaceutical First Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded.

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.45 per share a year ago.

– Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM ® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass.